Pacific Biosciences of California, Inc. (PACB)
| Market Cap | 347.87M +5.2% |
| Revenue (ttm) | 160.03M +5.0% |
| Net Income | -128.58M |
| EPS | -0.43 |
| Shares Out | 310.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,318,967 |
| Open | 1.210 |
| Previous Close | 1.210 |
| Day's Range | 1.120 - 1.210 |
| 52-Week Range | 0.851 - 2.730 |
| Beta | 2.40 |
| Analysts | Hold |
| Price Target | 1.83 (+63.39%) |
| Earnings Date | May 7, 2026 |
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified... [Read more]
Financial Performance
In 2025, PACB's revenue was $160.01 million, an increase of 3.89% compared to the previous year's $154.01 million. Losses were -$546.38 million, 76.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PACB stock is "Hold." The 12-month stock price target is $1.83, which is an increase of 63.39% from the latest price.
News
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers Multinational study shows how one comprehe...
PacBio price target raised to $1.50 from $1 at Barclays
Barclays raised the firm’s price target on PacBio (PACB) to $1.50 from $1 and keeps an Underweight rating on the shares.
PacBio sees FY26 revenue $165M-$175M, consensus $174.42M
18:02 EDT PacBio (PACB) sees FY26 revenue $165M-$175M, consensus $174.42M
Pacific Biosciences of California Earnings Call Transcript: Q1 2026
Record consumable revenue and strong clinical adoption offset weaker instrument sales due to funding pressures. Guidance for 2026 was lowered, but consumables and new product launches are expected to drive growth, with EMEA leading regional performance.
PacBio Announces First Quarter 2026 Financial Results
MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.
PacBio, Lucid Genomics announces collaboration to advance tertiary analysis
PacBio (PACB) and Lucid Genomics announced that Lucid Genomics has joined the PacBio Compatible partner program as a solution for tertiary analysis of data generated on PacBio long-read sequencing ins...
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem Expands access to streamlined genomic data analysis across the PacBio partner ecosystem
PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thur...
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research New extraction-to-library prep workflow ...
PacBio price target lowered to $1 from $1.50 at Barclays
Barclays lowered the firm’s price target on PacBio (PACB) to $1 from $1.50 and keeps an Underweight rating on the shares. The firm adjusted targets in the life science and…
PacBio HiFi selected by Basecamp Research AI lab
PacBio (PACB) announced that Basecamp Research, a frontier AI lab for therapeutic design, has selected PacBio HiFi sequencing on the Revio system to generate large-scale environmental and host-associa...
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics PacBio's Revio system and SPRQ-Nx chemistry to...
PacBio downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded PacBio (PACB) to Underweight from Equal Weight with a price target of $1.50, down from $2. The shares have a “tough setup” over the near-term, the analyst tells…
PacBio downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded PacBio (PACB) to Underweight from Equal Weight with a $1.50 price target
PacBio appoints Gibson to Board of Directors
PacBio (PACB) announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (RXRX). Published...
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing Proven experience in leveraging AI in biolog...
Pacific Biosciences of California Transcript: TD Cowen 46th Annual Health Care Conference
The company is poised for significant growth, driven by innovative long-read sequencing technology, global clinical adoption, and improved economics through SPARQ-Nx chemistry. Clinical revenue is accelerating, with large-scale projects and international markets fueling expansion, while management expects the clinical segment to surpass half of total revenue within five years.
PacBio files automatic mixed securities shelf
16:42 EST PacBio (PACB) files automatic mixed securities shelf
PacBio, DNAstack launhces global federated HiFi whole genome dataset
PacBio (PACB) announced a collaboration with DNAstack to power the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collabora...
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
Collaboration powers secure international data sharing through the HiFi Solves Global Consortium Collaboration powers secure international data sharing through the HiFi Solves Global Consortium
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate...
Pacific Biosciences of California Earnings Call Transcript: Q4 2025
Q4 and full year 2025 saw record consumable revenue and strong instrument placements, with clinical adoption driving growth despite academic funding headwinds. 2026 guidance projects 8% revenue growth, margin expansion, and continued focus on long-read sequencing and cost discipline.
PacBio reports Q4 EPS (12c), consensus (13c)
Reports Q4 revenue $44.65M, consensus $42.79M. “Our fourth quarter results exceeded expectations, with revenue growing 14% year-over-year and 16% sequentially,” said Christian Henry, president and CEO...
PacBio announces collaboration with iHope
PacBio (PACB) announced a collaboration with iHope to integrate PacBio’s HiFi long-read whole-genome sequencing into iHope’s international network. “We’ve been impressed with the progress iHope has ma...
PacBio completes sale of short-read sequencing assets
PacBio (PACB) announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent,...